Molecular Partners AG
Molecular Partners AG develops DARPin therapeutics for cancer, including radiopharmaceuticals for targeted alpha therapy and immune cell engagers.
20-FAug 27Latest SEC filing, period to Jun 30
Aug 25Latest story
Sign inSign inMolecular Partners AG develops DARPin therapeutics for cancer, including radiopharmaceuticals for targeted alpha therapy and immune cell engagers.